Effect of Bacillus licheniformis on gut flora and barrier function in patients with decompensated cirrhosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014600

Enrollment

Unknown

Registered

2018-01-23

Start date

2018-02-26

Completion date

Unknown

Last updated

2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal flora and intestinal mucosal barrier function in patients with decompensated cirrhosis

Interventions

test group:Experimental group: The comprehensive treatment program contains probiotics (Bacillus licheniformis 0.25g / capsule, 2 capsules each time, 3 times / day)

Control group:Control group: The combined treatment did not contain any probiotics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) patients with clinical diagnosis of decompensated liver cirrhosis; (2) One or more of gastrointestinal symptoms such as abdominal flora, abdominal distension, diarrhea, loss of appetite, fatigue and other digestive system symptoms detected by the hospital after the test; (3) patients signed informed consent, and conditional follow-up.

Exclusion criteria

Exclusion criteria: (1) Serious organic disease such as cardiovascular, brain, lung, kidney or other serious organ diseases, mental illness or non-cooperation, serious endocrine system, immune system diseases, pregnant or lactating women; (2) with the following diseases: cirrhosis with hepatocellular carcinoma, clear infection outside the digestive tract, gastrointestinal bleeding complicated with cirrhosis after transjugular intrahepatic portosystemic shunt (TiPPS), patients with diseases other than liver Caused by chronic diarrhea, malabsorption of illnesses; previous history of gastrointestinal or abdominal surgery; (3) antibiotics, probiotics, lactulose, acid-suppressing drugs and gastrointestinal motility drugs which can affect the intestinal flora during the recent 2 weeks and during treatment; (4) patients do not agree to the group, poor compliance can not continue to check and treatment.

Design outcomes

Primary

Measure	Time frame
Intestinal changes in the environment;	—

Secondary

Measure	Time frame
Clinical symptoms evaluation;Intestinal barrier function evaluation - blood biochemical indicators;Intestinal barrier function assessment - blood ammonia;	—

Countries

China

Contacts

Public ContactCao Jianbiao

PLA General Hospital

caojianbiao@sina.com+86 13521849114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026